drugset / Trial / NCT01091259
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.
Timeline
- Start
- 2010-03
- Primary completion
- 2014-02
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Irinotecan | Small molecule | 175 mg/m2 | — |